JP2023550310A5 - - Google Patents
Info
- Publication number
- JP2023550310A5 JP2023550310A5 JP2023528093A JP2023528093A JP2023550310A5 JP 2023550310 A5 JP2023550310 A5 JP 2023550310A5 JP 2023528093 A JP2023528093 A JP 2023528093A JP 2023528093 A JP2023528093 A JP 2023528093A JP 2023550310 A5 JP2023550310 A5 JP 2023550310A5
- Authority
- JP
- Japan
- Prior art keywords
- vista
- agonist
- antibody
- human
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063109584P | 2020-11-04 | 2020-11-04 | |
| US63/109,584 | 2020-11-04 | ||
| PCT/US2021/058020 WO2022098846A1 (en) | 2020-11-04 | 2021-11-04 | Vista agonist for treatment/prevention of ischemic and/or reperfusion injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550310A JP2023550310A (ja) | 2023-12-01 |
| JP2023550310A5 true JP2023550310A5 (https=) | 2024-11-07 |
Family
ID=81458372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528093A Pending JP2023550310A (ja) | 2020-11-04 | 2021-11-04 | 虚血及び／または再灌流障害の治療／予防のためのｖｉｓｔａアゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230399405A1 (https=) |
| EP (1) | EP4240409A4 (https=) |
| JP (1) | JP2023550310A (https=) |
| KR (1) | KR20230142828A (https=) |
| CN (1) | CN116600826A (https=) |
| AU (1) | AU2021373781A1 (https=) |
| CA (1) | CA3197359A1 (https=) |
| WO (1) | WO2022098846A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024172543A1 (ko) * | 2023-02-17 | 2024-08-22 | 뉴패스바이오(주) | Igsf11-fc 융합 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 자가면역질환 또는 염증성 질환의 예방 또는 치료용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6285923B2 (ja) * | 2012-06-22 | 2018-02-28 | トラスティーズ・オブ・ダートマス・カレッジ | 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用 |
| US9381244B2 (en) * | 2012-09-07 | 2016-07-05 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
| BR112015013431A2 (pt) * | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| KR20230119259A (ko) * | 2016-04-15 | 2023-08-16 | 이뮤넥스트, 인크. | 항-인간 vista 항체 및 이의 용도 |
| WO2017181109A1 (en) * | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
-
2021
- 2021-11-04 CA CA3197359A patent/CA3197359A1/en active Pending
- 2021-11-04 US US18/035,399 patent/US20230399405A1/en active Pending
- 2021-11-04 JP JP2023528093A patent/JP2023550310A/ja active Pending
- 2021-11-04 WO PCT/US2021/058020 patent/WO2022098846A1/en not_active Ceased
- 2021-11-04 KR KR1020237018789A patent/KR20230142828A/ko active Pending
- 2021-11-04 CN CN202180084646.0A patent/CN116600826A/zh active Pending
- 2021-11-04 AU AU2021373781A patent/AU2021373781A1/en active Pending
- 2021-11-04 EP EP21890045.4A patent/EP4240409A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8784822B2 (en) | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis | |
| CN100562339C (zh) | 小儿慢性关节炎相关疾病治疗剂 | |
| US8828393B2 (en) | Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonist | |
| CN111068062A (zh) | 治疗白介素-6相关疾病的方法 | |
| MX2011003328A (es) | Metodos para tratar inflamacion. | |
| AU2020319899B2 (en) | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics | |
| US9545441B2 (en) | Treatment of diabetes | |
| RU2020128111A (ru) | ВЕДЕНИЕ БЕЛКОВ СЛИЯНИЯ IL-22 Fc ДЛЯ ЛЕЧЕНИЯ | |
| JP2020521765A (ja) | 慢性腎疾患の治療のためのデュラグルチド | |
| JP2023550310A5 (https=) | ||
| EP3371218A1 (en) | Treatment paradigm | |
| JP2022514381A5 (https=) | ||
| ZA200608884B (en) | Methods of treating autoimmune and inflammatory diseases | |
| EP3590535A1 (en) | Preventive or therapeutic agent for htlv-1-associated myelopathy using low-dose anti-ccr4 antibody | |
| JP2018065796A (ja) | クローン病を治療するための医薬組成物 | |
| US9486475B2 (en) | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains | |
| CN1163272C (zh) | Tnf拮抗剂作为用于治疗脓毒性疾病的药物的用途 | |
| JP2023550310A (ja) | 虚血及び／または再灌流障害の治療／予防のためのｖｉｓｔａアゴニスト | |
| Brunger et al. | Obesity-induced AA amyloidosis: A diagnosis of exclusion | |
| Schafernak et al. | Co-existent crescentic glomerulonephritis and renal amyloidosis: a case report and literature review | |
| JP2023505219A (ja) | 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 | |
| WO2024036385A1 (en) | Treatment of myocarditis by administration of anti-interleukin-6 antibodies | |
| EP4035663A1 (en) | Use of progestin in treating cytokine release syndrome | |
| US20210017278A1 (en) | Treatment and Prophylaxis of Amyloidosis | |
| JP2017154975A (ja) | クローン病を治療するための医薬組成物 |